News

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.

Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.

In this episode, hosts explore real-world data on Beta Bionics' iLet automated insulin delivery system for diabetes management.

Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.

At ATS 2025, these post-hoc analysis findings on taladegib (ENV-101) highlight the treatment’s efficacy for idiopathic pulmonary fibrosis.

Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.

Veligrotug shows promising long-term Phase 3 results for treating thyroid eye disease, supporting its BLA submission in the second half of 2025.

In this interview at ATS 2025, Arthur Reingold, MD, highlights the role of pulmonologists and other health care providers in combatting vaccine misinformation.

The allergy medications of cetirizine or levocetirizine have led to pruritus in some patients who stopped using the medications after using them daily for a few months or years.

Shultz discusses the impact of lotilaner ophthalmic solution 0.25% to treat active Demodex blepharitis in patients with meibomian gland dysfunction.

This analysis highlights rademikibart’s effect on blood eosinophil counts in those with asthma, exploring whether there was an IL-4Rα class effect.

Miranti shared 2025 acne and rosacea trends, as well as an overlapping treatment option for patients with both conditions, at New Wave Dermatology.

Abramson's presented operation indicates that Coats disease can manifest bilaterally and is potentially caused by multiple independent genes.

Williams discusses her takeaways from the 2025 Envision conference and her expectations for the future of both ophthalmology and its practitioners.

This interview at ATS 2025 highlights the talk given by Grace Lee, MD, MPH, regarding the policy side of public health concerns over widespread immunization.

A post-hoc analysis of SURMOUNT-OSA highlights tirzepatide’s consistent benefit across all baseline OSA severity groups.

The FIBRONEER-IPF and FIBRONEER-ILD data highlight nerandomilast’s efficacy and safety in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

This analysis highlights the rapid improvements seen in patients with uncontrolled asthma within 24 hours of their initial rademikibart dose.

The pooled analysis of ENHANCE clinical trial program data highlight improvements in HRQoL, dyspnea, and COPD symptoms with ensifentrine monotherapy.

Nearly all treated patients received glucocorticoids, but many quickly needed later-line therapies, especially those with non-incident pulmonary sarcoidosis.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

The ProVENT data highlight dupilumab’s efficacy in treating severe asthma, with improvements in control, quality of life, and exacerbations being observed.

Phase 3 BATURA data reveal a 47% reduction in the risk of severe exacerbations in mild asthma with albuterol/budesonide (Airsupra) versus albuterol alone.

In this analysis, investigators found consistent benefits over placebo among children with type 2 asthma treated with dupilumab, regardless of condition length.

Olezarsen shows promising results in reducing triglyceride levels for patients with moderate hypertriglyceridemia, offering hope for better cardiovascular health.

LED BLU-U, used in combination with LEVULAN KERASTICK, is capable of treating minimally to moderately thick actinic keratoses.

At 2025 New Wave Dermatology, HCPLive spoke with Miranti on treating the 4 pillars of pathogenesis, including sebum production, inflammation, and more.

Interim results from the ongoing trial indicated achievement of all efficacy endpoints, with no safety concerns reported.